Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Lasiocarpine Hydrochloride, (1s-(1alpha(z),7(2s*,3r*),7aalpha))-isomer
2. Lasiocarpine Sulfate, (1s-(1alpha(z),7(2s*,3r*),7aalpha))-isomer
1. 7-angelyleuropine
2. (-)-lasiocarpine
3. 303-34-4
4. Europine 7-angelate
5. Nsc-30625
6. Nci-c01478
7. S770100q96
8. Rcra Waste Number U143
9. Mls002639334
10. Heliotridine Ester With Lasiocarpum And Angelic Acid
11. Ccris 355
12. Nsc30625
13. C21h33no7
14. Hsdb 6062
15. Unii-s770100q96
16. Nsc 30625
17. Heliotridine Ester With Lasiocarpum & Angelic Acid
18. Ai3-51770
19. Lasiocarpine [mi]
20. Lasiocarpine, Hplc Grade
21. Rcra Waste No. U143
22. Lasiocarpine [hsdb]
23. Lasiocarpine [iarc]
24. Schembl168932
25. Chembl1999554
26. Mfcd31631257
27. Zinc61997632
28. Heliosupine Methyl Ether [mi]
29. Akos030501885
30. (z)-2-methylcrotonic Acid, 2,3-dihydroxy-2-(1-methoxyethyl)-3-methylbutyrate (ester)
31. (7alpha-angelyloxy-5,6,7,8alpha-tetrahydro-3h-pyrrolizin-1-yl)methyl-2,3-dihydroxy-2-(1'-methoxyethyl)-3-methylbutyrate
32. 2,3,5,7alphabeta-tetrahydro-1-hydroxy-1h-pyrrolizine-7-methanol-1-angelate-7-(2,3-dihydroxy-2(1-methoxyethyl))-3-methyl-butyrate
33. 2-butenoic Acid, 2-methyl-, 7-((2,3-dihydroxy-2-(1-methoxyethyl)-3-methyl-1-oxobutoxy)methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl Ester, (1s-(1alpha(z),7(2s*,3r*),7aalpha))-
34. Wln: T55 An Cutj D1ovxqxq1 & 1 & Y1 & O1 Fovy1 & U2
35. (1s,7ar)-7-((((r)-2,3-dihydroxy-2-((s)-1-methoxyethyl)-3-methylbutanoyl)oxy)methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (z)-2-methylbut-2-enoate
36. 2-butenoic Acid, 2-methy-,(1s,7ar)-7-(((2r)-2,3-dihydroxy-2-((1s)-1-methoxyethyl)-3-methyl-1-oxobutoxy)methyl)-2,3,5,7a-tetrahydro-1h-ester, (2z)-
37. 2-butenoic Acid, 2-methyl-, 7-((2,3-dihydroxy-2-(1-methoxyethyl)-3-methyl-1-oxobutoxy)methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl Ester, (1s-(1.alpha.(z),7(s*(r*)),7a.alpha.))-
38. 2-butenoic Acid, 2-methyl-, 7-((2,3-dihydroxy-2-(1-methoxyethyl)-3-methyl-1-oxobutoxy)methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl Ester, (1s-(1alpha(z),7(2s*,3r*),7a Alpha))-
39. 2-butenoic Acid, 7-[[2,3-dihydroxy-2-(1-methoxyethyl)-3-methyl-1-oxobutoxy]methyl]-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl Ester, [1s-[1.alpha.(z),7(2s*,3r*),7a.alpha.]]-
| Molecular Weight | 411.5 g/mol |
|---|---|
| Molecular Formula | C21H33NO7 |
| XLogP3 | 0.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 10 |
| Exact Mass | 411.22570239 g/mol |
| Monoisotopic Mass | 411.22570239 g/mol |
| Topological Polar Surface Area | 106 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 699 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 4 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
LASROCARPINE (RANDOMLY LABELLED, 44% IN THE AMINO ALCOHOL) WAS ADMIN IP TO RATS (TOTAL DOSE, 5 MG) DISTRIBUTION OF LABEL AFTER 4 HR WAS AS FOLLOWS: CARCASS, 6.4%; INTESTINES, 8.6%; TESTES, 0.1%; LUNG, 0.05%; KIDNEY, 0.26%; HEART, 0.05%; SPLEEN, 0.01%; BRAIN, 0.03%; URINE, 27.2%; LIVER, 2.8%, EXPIRED CO2, 9.3% FRACTIONATION OF LIVER RESULTED IN 1.73% IN A TRICHLOROACETIC ACID EXTRACT, 0.6% IN PROTEIN, 0.48% IN LIPID & 0.005% IN NUCLEIC ACIDS.
IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V10 285 (1976)
STUDIES WITH LASIOCARPINE HAVE CONFIRMED THE FORMATION OF PYRROLIC METABOLITES BY THE MIXED-FUNCTION OXIDASE SYSTEM OF THE MICROSOMAL FRACTION OF RAT LIVER. DEHYDROHELIOTRIDINE HAS BEEN ISOLATED & IDENTIFIED AS A PRODUCT OF MICROSOMAL OXIDATION OF LASIOCARPINE.
IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V10 285 (1976)
IN URINE ... OBTAINED 16 HR AFTER INJECTION ... TO RATS ... UNCHANGED LASIOCARPINE (1-1.5% OF DOSE), HELIOTRIDINE (1.5-3%), HELIOTRIDINE N-OXIDE (6%) & TRACES OF BASES WITH CHROMATOGRAPHIC PROPERTIES OF EUROPINE & 7-ANGELYHELIOTRIDINE (EXPECTED PRODUCTS OF PARTIAL HYDROLYSIS). ... METABOLITES IN 24-HR URINE SAMPLE ... 8.5% OF ADMIN LASIOCARPINE.
IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V10 286 (1976)
HUMAN EMBRYONIC LIVER SLICES CONVERTED THE PYRROLIZIDINE ALKALOID LASIOCARPINE INTO PYRROLES, AS INDICATED BY A POS EHRLICH COLOR REACTION, WHEREAS LUNG TISSUE DID NOT.
ARMSTRONG SJ, ZUCKERMAN AJ; NATURE (LONDON) 228 (5271): 569 (1970)
Death may be due to actual liver damage or to the upsetting of the copper storage mechanism which leads to a build-up of copper in the organ, resulting in the acute hemolytic crisis associated with chronic copper poisoning.
Humphreys, D.J. Veterinary Toxicology. 3rd ed. London, England: Bailliere Tindell, 1988., p. 236
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
69
PharmaCompass offers a list of Lasiocarpine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lasiocarpine manufacturer or Lasiocarpine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lasiocarpine manufacturer or Lasiocarpine supplier.
PharmaCompass also assists you with knowing the Lasiocarpine API Price utilized in the formulation of products. Lasiocarpine API Price is not always fixed or binding as the Lasiocarpine Price is obtained through a variety of data sources. The Lasiocarpine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lasiocarpine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lasiocarpine, including repackagers and relabelers. The FDA regulates Lasiocarpine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lasiocarpine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lasiocarpine supplier is an individual or a company that provides Lasiocarpine active pharmaceutical ingredient (API) or Lasiocarpine finished formulations upon request. The Lasiocarpine suppliers may include Lasiocarpine API manufacturers, exporters, distributors and traders.
Lasiocarpine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lasiocarpine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lasiocarpine GMP manufacturer or Lasiocarpine GMP API supplier for your needs.
A Lasiocarpine CoA (Certificate of Analysis) is a formal document that attests to Lasiocarpine's compliance with Lasiocarpine specifications and serves as a tool for batch-level quality control.
Lasiocarpine CoA mostly includes findings from lab analyses of a specific batch. For each Lasiocarpine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lasiocarpine may be tested according to a variety of international standards, such as European Pharmacopoeia (Lasiocarpine EP), Lasiocarpine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lasiocarpine USP).
